Mobile

A study comparing bevacizumab with placebo when added to the current standard of treatment (temozolomide and radiotherapy, followed by temozolomide) in patients with a type of newly diagnosed brain tu...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006146-26

A study comparing bevacizumab with placebo when added to the current standard of treatment (temozolomide and radiotherapy, followed by temozolomide) in patients with a type of newly diagnosed brain tumor named Glioblastoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To demonstrate the superiority in overall survival (OS) when bevacizumab is added to temozolomide with radiotherapy followed by temozolomide for the treatment of patients with newly diagnosed glioblastoma • To demonstrate the superiority in progression-free survival (PFS) as assessed by the investigator (using adapted MacDonald criteria) when bevacizumab is added to temozolomide with radiotherapy followed by temozolomide for the treatment of patients with newly diagnosed glioblastoma

Critère d'inclusion

  • Glioblastoma

Liens